The shared findings across models, along with the clinical observation that eIF2B partial loss-of-function mutations primarily manifest as a neurological disease in humans, strongly suggest that the CNS is particularly sensitive to eIF2B dysfunction. Here, EIF2B5 is linked to nervous system disorder.